Trump, Pfizer announce settlement to decrease U.S. drug costs

President Donald Trump on Tuesday introduced an settlement with Pfizer to voluntarily promote its drugs for much less, as his administration pushes to hyperlink U.S. drug costs to cheaper ones overseas.

Pfizer has agreed to take measures to scale back U.S. drug costs, together with promoting its current medicine to Medicaid sufferers on the lowest worth supplied in different developed nations, or what Trump calls the most-favored-nation worth, based on the president. Pfizer may even assure the identical “most-favored-nation” pricing on its new medicine for Medicare, Medicaid and business payers.

As a part of the deal, Pfizer has additionally agreed to a three-year grace interval throughout which the corporate’s merchandise will not face pharmaceutical-specific tariffs – so long as the drugmaker additional invests in U.S. manufacturing. The corporate plans to take a position $70 billion to reshore home drug manufacturing and analysis services.

Shares of Pfizer rose greater than 4% on Tuesday after the announcement.

“Pfizer has agreed to offer a few of the hottest present drugs to our shoppers at closely discounted costs anyplace between 50% and even 100%,” Trump stated, including that these medicine might be accessible for direct buy at a reduction on-line on a web site the administration is looking TrumpRx.gov.

Trump stated he is working with different drugmakers to safe comparable agreements over the following week, including that Pfizer is the primary.

“If we do not make a deal, we’ll tariff them,” he stated of the opposite firms’ medicine.

The deal comes as Pfizer and 16 different drugmakers face Trump’s Monday deadline to take steps to decrease drug costs, as outlined in letters from the president. Trump in Might signed an govt order reviving a controversial plan, the “most favored nation” coverage, that goals to tie the costs of some medicines within the U.S. to the considerably decrease ones overseas.

In the course of the press convention, Pfizer CEO Albert Bourla stated the corporate glad all 4 of the requests Trump outlined in his letter. Among the many different steps is pursuing harder worth negotiations overseas and adopting fashions that promote its medicines on to shoppers or companies.

“The large winner clearly would be the American sufferers, there isn’t any doubt,” Bourla stated. “They’re those that can see a big influence on their potential to purchase medicines.” However he stated “American innovation and and the American economic system” may even be “winners” with the settlement.

Pfizer stated it’s going to provide a big share of its primacy care remedies and sure specialty branded medicine at reductions of fifty% on common and as much as 85%, based on a launch from the corporate.

In a separate assertion Tuesday, Pfizer stated greater than 100 million sufferers are impacted by ailments these medicines deal with, corresponding to migraines, rheumatoid arthritis, menopause and atopic dermatitis.

The corporate offered examples of discounted medicine beneath TrumpRx.gov. Duavee, a remedy for sure menopause signs, might be accessible for as little as $30 on the positioning, which is an 85% low cost to its present worth.

Sufferers may even have the ability to pay as little as $162 – an 80% discount to the present worth – for prescription ointment Eucrisa, which is used to deal with mild-to-moderate eczema. Tovias, a drugs for overactive bladder, may even be accessible on TrumpRx.gov for as little as $42, which is a 85% low cost to the present worth.

Pfizer stated it additionally plans to supply merchandise corresponding to Abrilada for autoimmune ailments at a 60% low cost, Xeljanz for rheumatoid arthritis at a 40% low cost and the migraine drug Zazvpret at 50% low cost.

These medicine do not seem like vital income drivers for Pfizer. The corporate’s quarterly and full-year earnings studies solely embody product-specific income for Xeljanz, which generated $349 million in worldwide gross sales in 2024. Gross sales of the drug fell 29% operationally from 2023, primarily because of decrease demand globally in addition to decrease internet costs within the U.S.

The deal comes as drugmakers brace for Trump’s deliberate tariffs on prescription drugs imported into the nation. Trump stated in a Fact Social publish Thursday that the U.S. will impose a 100% tariff on “any branded or patented Pharmaceutical Product” getting into the nation from Oct. 1.

The measure is not going to apply to firms constructing drug manufacturing crops within the U.S., Trump stated. He added that the exemption covers tasks the place development has began, together with websites which have damaged floor or are beneath development.

In a be aware on Tuesday, BMO Capital Markets analyst Evan Seigerman stated the deal is optimistic for Pfizer’s inventory and the broader pharmaceutical sector, because it “provides certainty and shifts POTUS insurance policies doubtlessly away from Pharma tariffs.”

“As we speak’s deal appears to set a path for different pharmaceutical gamers to observe, permitting for headline pricing concessions and a Trump ‘win’ with out extra punitive implementation” of probably the most favored nation coverage or tariffs, he added.